Oxygen Method

The Method - OXYGEN

Most of what gets sold as "wellness" doesn't work. Or works at doses no one actually takes. Or works for reasons the marketing gets wrong.

Exposure Method exists because there are four categories of stressor where the mechanism is real, the research is mature enough to act on, and the equipment can be evaluated on specs instead of vibes. Cold. Heat. Oxygen. Light.

This page lays out what each one does at the cellular level, who established it in the research, what dose people actually run, what evidence weight sits behind each claim, and the language we use when we talk about it. Read it once and you'll be able to walk into any conversation about recovery hardware and tell the difference between a brand that's read the papers and a brand that's read the marketing.

The standard for our shelf: a product earns space here when the supplier can articulate mechanism, cite the research behind their dose, and tell you what their device doesn't do.

How we weight the evidence

Not every claim on this page has the same strength behind it. We grade the evidence using established academic frameworks — GRADE methodology (the WHO and Cochrane global standard) and Oxford Centre for Evidence-Based Medicine Levels of Evidence — and we tag each finding with one of four composite weights:

[A] Strong — multiple randomized trials, large samples, replicated across independent labs. Confidence is high.
[B] Moderate — solid studies, but smaller samples or observational design. Confident the effect is real; uncertain about exact magnitude.
[C] Emerging — early studies suggest the effect, but the field is still building toward consensus.
[D] Mechanism-only — the biological mechanism is plausible, but human outcome data is limited or based on animal models. Take it as a hypothesis worth testing, not an established fact.

Why this matters to you: most of the recovery-equipment evidence base is currently in the [B] to [D] range. Some claims (KIHD sauna cohort mortality reduction, hair regrowth from photobiomodulation, cold's hypertrophy attenuation when timed wrong) are well-supported [A] or [B] tier. Other claims (mild HBOT outcomes at 1.3 ATA, infrared sauna long-term outcomes, transcranial PBM for mood) are still emerging [C] or mechanism-only [D]. We label every major claim on this page so you can calibrate trust.

This is not a proprietary system. The methodology is a faithful application of GRADE and Oxford CEBM. The brand value is that we apply it transparently — most recovery-equipment retailers do not.

Oxygen Exposure

Pressure-driven oxygen saturation. Hyperbaric oxygen exposure forces dissolved O2 into plasma at levels not reachable through breathing alone.

The mechanism

Atmospheric pressure determines how much gas dissolves in liquid. This is Henry's Law. Increase the pressure on someone breathing oxygen, and you saturate the plasma — not just the hemoglobin — with O2. Tissues then receive oxygen via diffusion gradient, reaching areas where blood flow is compromised or capillaries are damaged [B: well-established physiological mechanism].

Downstream:

Stem cell mobilization — endothelial progenitor cells release from bone marrow at 3–5x baseline after HBOT sessions [D for consumer-chamber relevance: the 3–5x figure is from Thom 2006/2011 work conducted predominantly at 2.0+ ATA. Whether consumer mild-HBOT chambers at 1.3–1.5 ATA deliver the same magnitude of EPC mobilization is not directly established by 1.3 ATA-specific mechanism trials]
VEGF (vascular endothelial growth factor) upregulates, driving neovascularization [B at hard HBOT pressures]
Mitochondrial biogenesis — more mitochondria per cell [C: mechanism-evidence at hard HBOT; less clear at consumer pressures]
Hyperoxic-hypoxic paradox — Efrati and colleagues propose that cycling between high O2 and ambient triggers adaptation more powerfully than sustained hyperoxia [D: framing from the Efrati-group hypothesis literature; the paradox concept itself is mechanism-plausible but specific outcome trials at consumer pressures are sparse]

Hard vs. mild HBOT — the distinction that matters

This is the single most evidence-sensitive section on the page. The brand's positioning depends on getting this right.

Hard HBOT (medical): 2.0–3.0 ATA, 100% oxygen, hospital-grade chambers. FDA-cleared for 14 specific conditions including non-healing wounds, carbon monoxide poisoning, decompression sickness, radiation tissue damage, and severe anemia [A: regulatory fact verifiable in FDA + UHMS guidance + ECHM Consensus 2017]. Most published efficacy research occurred at 2.0+ ATA.

Mild HBOT / mHBOT (wellness): 1.3–1.5 ATA, room air or supplemental oxygen via concentrator. Most consumer chambers fall here.

The dose-response evidence is clear and pressure-dependent. Harch et al. 2022 Frontiers in Neurology (PMID 35370896) systematic review of HBOT for persistent post-concussion symptoms found statistically significant effects clustered at 1.5 ATA × 40 sessions and 2.0 ATA × 40 sessions [B: systematic review of mostly Efrati-group RCTs + replications, trending A given synthesis layer]. Studies at 1.3 ATA × fewer sessions showed weaker effects.

Bottom line: Consumer chambers at 1.3 ATA extrapolate from clinical work done at 1.5–2.0 ATA [D: the 1.3 ATA-specific RCT base is much thinner than chamber marketing implies]. The extrapolation may be valid, but it is not currently proven by 1.3 ATA-specific trial evidence. We say this directly because customers deserve to know it before they spend $15,000 on a chamber.

The research

Shai Efrati (Tel Aviv University / Sagol Center) led the landmark cognitive HBOT trials — Alzheimer's, post-stroke, post-TBI cognitive recovery, Long COVID, and most recently aging biomarkers [B: multiple Efrati-group RCTs across indications; Cohen's d 0.4–0.6 on cognitive endpoints. Honest caveat: most of the cognitive HBOT trial work is from this single group. Independent replication outside Israel is sparse. Treat findings as "plausible and provisionally accepted; awaiting independent replication"]. His work occurs at higher ATA than consumer chambers reach.

Paul Harch has spent decades on neurological HBOT applications, particularly traumatic brain injury and post-concussive syndrome [C: Harch 2017 mTBI + PTSD at 1.5 ATA replicates Boussi-Gross].

Jason Sonners runs the clinical hyperbaric practice many in this space consider the reference operation. His clinical observations on mild HBOT outcomes are widely cited; the formal trial evidence on consumer-pressure chambers is still maturing.

Cochrane counterweight. Bennett et al. 2012 [A: Cochrane systematic review of HBOT for TBI, PMID 23235612] found HBOT reduces risk of death in acute TBI but quality-of-life data was weak. The Cochrane is the conservative voice; cite alongside Harch 2022 to show both sides of the evidence base.

⚠️ Important Pass 3 caveat (Hadanny 2024 PTSD dose-response): In the PTSD dose-response analysis [C: Hadanny 2024 Frontiers in Neurology PMID 38882688], 30–39% of subjects experienced reversible exacerbation of emotional symptoms at the highest oxygen doses. Higher dose drove larger benefit AND larger adverse emotional response. This is a contraindication-adjacent finding worth knowing for HBOT-curious customers with trauma-adjacent indications.

The protocol

Hard HBOT (medical): 90 min at 2.0 ATA, 5 days/week, 40–60 session courses [B trending A at this dose]
Intermediate (1.5 ATA): 60 min at 1.5 ATA, 5 days/week, 40 sessions [B: strongest consumer-adjacent evidence]
Consumer mild (1.3 ATA): 60–90 min, 5 days/week course [D / mechanism-only at this pressure]
Sensation: Ear pressure during pressurization and depressurization — the only skill is Eustachian tube clearing
Contraindications: Untreated pneumothorax (absolute), recent ear surgery, certain chemotherapy regimens, severe COPD with CO2 retention. See Lin 2023 systematic review of HBOT adverse effects [B: PMC10232961] for the full safety profile.

The vocabulary

ATA (atmospheres absolute) — pressure unit; 1 ATA = sea level. Henry's Law — gas solubility scales with pressure. Hyperoxic-hypoxic paradox — Efrati-group hypothesis about oscillating O2 levels as adaptive trigger. Neovascularization / angiogenesis — formation of new blood vessels. VEGF — vascular endothelial growth factor. Stem cell mobilization — release of progenitor cells from marrow. Oxygen toxicity — real at high doses/durations; relevant at 2.0+ ATA for extended sessions. Off-label — clinical use beyond FDA-cleared indications.

What we look for in an oxygen supplier

Pressure capacity and stability matter most. A chamber that holds 1.5 ATA without drift, with a compressor quiet enough to use daily, with a documented emergency depressurization protocol, is a different product than a chamber that wobbles between 1.2 and 1.4 ATA in a noisy compressor enclosure. Concentrator quality (delivered O2 percentage), chamber material, and accessibility are the rest of the spec sheet. We require suppliers to articulate mechanism, cite research at the pressure they're selling, and surface the dose-evidence gap honestly. We don't carry chambers without clear pressure documentation, and we don't permit 1.3 ATA chambers to be marketed using 2.0 ATA Efrati-group trial evidence.